Urinary NMP22 for the Detection of Recurrence After Transurethral Resection of Transitional Cell Carcinoma of the Bladder: Experience on 137 Patients

Serretta, Vincenzo; Presti, Dario; Vasile, P.; Gange, E.; Espósito, Elisa; Menozzi, I.

doi:10.1016/s0022-5347(05)68642-9

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of blood or inflammatory cell contamination is one of the limitations in the clinical application of many bladder cancer screening tests including urine cytology, BTA-Stat, and NMP22. 26,27 To explore the feasibility of urine sample as a source of tumour cells for the determination of gene expression signature, HOXA13-BLCA-4 (uRNA-S) was used. Given the known inaccuracy in discriminating BTCC of stage Ta from those of stage T1 with clinical utility, 28 the actual accuracy of uRNA-S for the prediction of stages may exceed that which was observed here.…”

Section: Discussionmentioning

confidence: 99%

Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray

Guo

Che

Shi³

et al. 2011

cuaj

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray

Guo

Che

Shi³

et al. 2011

cuaj

View full text Add to dashboard Cite

show abstract

“…This marker is utilized for the follow-up of the response to therapy. High levels of this marker are also present in melanoma [294], pancreatic endocrine tumors [300,301] and medullary thyroid cancer [302,303]. NSE can be readily detected with an Elisa kit (Alpha Diagnostic Intl., Inc.; San Antonio, TX).…”

Section: Neuron-specific Enolase (Nse)mentioning

confidence: 99%

Tumor markers currently utilized in cancer care

Romano¹

2015

MATER METHODS

View full text Add to dashboard Cite

A review of tumor markers that are currently used in cancer care. Tumor marker Type of tumor/tumors Application 21-Gene signature (Oncotype DX). Breast cancer. Assess risk of tumor recurrence. 70-Gene signature (Mammaprint). Breast cancer. Assess risk of tumor recurrence. Anaplastic lymphoma kinase (ALK) (mutations). Non-small cell lung cancer and anaplastic large cell lymphoma. Diagnosis and determine type of treatment. BRAF (mutations). Melanoma, colorectal cancer and thyroid cancer. Diagnosis and determine type of treatment in patients with melanoma. Epidermal growth factor receptor (EGFR), or HER1 Cancers of the breast, head and neck, non-small cell lung, pancreas and colon. Predict outcomes and determine type of treatment. HER2, or HER2/neu, erbB-2, EGFR2 Breast cancer, stomach cancer and esophageal cancer. Predict outcomes and determine type of treatment. Hormone receptor (estrogen and progesterone) Breast cancer and gynecologic malignancies, such as endometrial stromal sarcomas and endometrial cancers. Predict outcomes and determine type of treatment. KIT Gastrointestinal stromal tumor and mucosal melanoma. Diagnosis and determine type of treatment. KRAS (mutations) Advanced colorectal cancer and lung cancer. Determine type of treatment. S-100 Melanoma. Diagnosis. Blood tests allow for the follow-up of the clinical course of the disease. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1). Breast cancer. To assess the aggressiveness of the malignancy and determine the type of treatment. Table 1. List of tumor markers that are detected in malignant tissues, other than the blood. Tumor markers detected in malignant tissues The detection of these tumor markers requires the removal of a biopsy from the patient [6-19]. In certain cases, biopsy-derived tumor markers are utilized just once, in order to confirm a diagnosis. The list of tumor markers that are analyzed in malignant tissues is summarized in Table 1. 21-Gene signature (Oncotype DX) This set of markers is utilized to assess the risk of the reappearance of the tumor in patients with breast cancer [9,26-28]. The 21-gene signature comprises genes that are related to the estrogen receptor (ESR1, PGR, BCL2, SCUBE2), HER2 (HER2 and GRB7), cell proliferation (Ki67, STK15, survivin, cyclin B1, MYBL2), cellular invasion (stromelysin3, cathepsin L2), macrophage marker CD68, anti-apoptotic genes (BAG1 and GSTM1) and five housekeeping genes that are used as reference (-actin, GAPDH, RPLPO, GUS and TFRC) [9, 26-28]. Oncotype DX is a gene-expression profiling that requires RNA samples derived from paraffinembedded tumor biopsies and was introduced for the first time in the U.S.A. market in 2004 (Genomic Health Inc., Redwood City, CA) [29]. 70-Gene signature (MammaPrint) This set of markers is utilized to assess the risk of the recurrence of the tumor in patients with breast cancer (for a review see references 31-35). In contrast to the 21-Gene signature (Oncotype DX), this assay needs a preparation of fresh tissues in a solution design...

show abstract

“…Retinoic acid negatively regulates AP-1-dependent gene expression (32). AP-1 directs the expression of a 1.2-kb annexin II mRNA in different cell systems (33)(34)(35)(36)(37)(38)(39)28).…”

Section: Annexin Ii: Structure and Functionmentioning

confidence: 99%

“…Annexin II has been found on the surface of many cell types including endothelial (1), lymphoma (38), leukemic cells (28), and cell lines derived from macrophages (67). On the cell surface of glioma and endothelial cells, annexin II binds to tenascin C, an extracellular matrix component and aids in initiating the migration through the extracellular matrix (33,68).…”

Section: Versatile Cellular Roles Of Annexin IImentioning

confidence: 99%

“…In gastric cancer tissues, its overexpression correlates with poor prognosis (70). Extracellular annexin II has also been reported to mediate tumor cell interaction with hepatic sinusoidal endothelial cells (33), as well as endothelial and glioma cell adhesion to matrix by binding to tenascin C (33,68). Annexin II also binds F-actin and may thus have a role in shape changes involved in movement of cells (71).…”

Section: Versatile Cellular Roles Of Annexin IImentioning

confidence: 99%

See 1 more Smart Citation